Post-hoc analyses of the recommended starting dose for Rytary based on “off” time
Objective: To determine whether correcting for “off” time duration improves the selection of the final LD dose when converting to extended-release carbidopa-levodopa capsules (ER CD-LD,…Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study
Objective: To compare the systemic levodopa exposure during administration of levodopa-entacapone-carbidopa (LECIG) intestinal gel with levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson's disease (PD) patients.…Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.